Ascendis Pharma (ASND) Reports Q2 Loss of EUR0.55/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. AMZN
10. LEN

Go back to Ascendis Pharma (ASND) Reports Q2 Loss of EUR0.55/Share

Ascendis Pharma A/S Reports Second Quarter 2018 Financial Results

August 29, 2018 4:01 PM EDT

- Continued advancement of endocrinology rare disease pipeline, paving way for application of TransCon technology in a new therapeutic area -

- Conference Call Today at 4:30 p.m. Eastern Time -

COPENHAGEN, Denmark, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the quarter ended June 30, 2018.

We continue to execute on our... More